Additional data presented at The International Liver Congressâ„¢ 2023 show clinical risk factors for PBC disease progression present in a broader population of UDCA-treated PBC patients
Read more at prnewswire.comCymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here